Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)
China · Delayed Price · Currency is CNY 19.83
+0.16 (0.81%)
At close: Aug 20, 2026
SHE:301263 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 10,078 | 12,278 | 6,348 | 6,948 | 7,683 | - | |
Market Cap Growth | -33.16% | 93.40% | -8.63% | -9.56% | - | - |
Enterprise Value | 9,897 | 12,121 | 6,066 | 6,271 | 6,685 | - |
Last Close Price | 19.83 | 24.11 | 12.37 | 13.21 | 14.33 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 428.80 | 58.66 | 43.37 | 44.00 | - |
Forward PE | - | 66.83 | 25.85 | 22.52 | 28.32 | - |
PS Ratio | 15.55 | 18.19 | 8.81 | 9.13 | 9.81 | - |
PB Ratio | 5.87 | 7.05 | 3.50 | 3.80 | 4.14 | - |
P/TBV Ratio | 9.67 | 9.71 | 4.56 | 4.86 | 4.36 | - |
P/FCF Ratio | - | - | 305.50 | - | 130.35 | - |
P/OCF Ratio | 123.24 | - | 71.07 | 74.29 | 51.63 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 15.27 | 17.96 | 8.41 | 8.24 | 8.53 | - |
EV/EBITDA Ratio | 283.61 | 174.16 | 37.24 | 28.37 | 29.48 | - |
EV/EBIT Ratio | - | 2075.39 | 55.12 | 34.14 | 34.32 | - |
EV/FCF Ratio | - | - | 291.92 | - | 113.43 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.23 | 0.21 | 0.13 | 0.10 | 0.01 | 0.15 |
Debt / EBITDA Ratio | 11.38 | 5.08 | 1.48 | 0.79 | 0.10 | 0.70 |
Debt / FCF Ratio | - | - | 11.68 | - | 0.39 | 1.45 |
Net Debt / Equity Ratio | -0.14 | -0.15 | -0.23 | -0.29 | -0.55 | -0.04 |
Net Debt / EBITDA Ratio | -7.53 | -3.71 | -2.59 | -2.40 | -4.52 | -0.18 |
Net Debt / FCF Ratio | 6.92 | 2.13 | -20.28 | 4.99 | -17.38 | -0.38 |
Asset Turnover | 0.26 | 0.28 | 0.32 | 0.36 | 0.53 | 0.74 |
Inventory Turnover | 2.59 | 3.12 | 3.33 | 3.64 | 4.18 | 3.70 |
Quick Ratio | 1.46 | 1.98 | 2.68 | 4.21 | 9.15 | 2.23 |
Current Ratio | 1.68 | 2.26 | 3.05 | 4.69 | 9.81 | 2.66 |
Return on Equity (ROE) | -1.31% | 0.72% | 5.32% | 8.33% | 13.62% | 18.47% |
Return on Assets (ROA) | -0.81% | 0.15% | 3.03% | 5.38% | 8.17% | 8.98% |
Return on Invested Capital (ROIC) | -2.16% | 0.41% | 7.51% | 13.78% | 21.71% | 17.07% |
Return on Capital Employed (ROCE) | -1.70% | 0.30% | 5.70% | 9.30% | 10.30% | 17.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.05% | 0.23% | 1.70% | 2.31% | 2.27% | - |
FCF Yield | -0.35% | -0.99% | 0.33% | -1.53% | 0.77% | - |
Dividend Yield | 0.21% | 0.17% | 1.35% | 1.89% | 2.26% | - |
Payout Ratio | - | 326.83% | 124.86% | 104.11% | 49.14% | 3.56% |
Buyback Yield / Dilution | -1.89% | 1.66% | 1.27% | -6.23% | -24.85% | -6.51% |
Total Shareholder Return | -1.69% | 1.83% | 2.62% | -4.34% | -22.59% | -6.51% |